期刊文献+

Small-cell carcinoma of the prostate with negative CD56,NSE,Syn,and CgA indicators:A case report 被引量:1

下载PDF
导出
摘要 BACKGROUND Small-cell carcinoma of the prostate(SCCP)is a clinically rare malignant tumor,accounting for<1%of all prostate tumors.However,negativity for all SCCP neuroendocrine markers is rare.Herein,we report a case of SCCP with completely negative neuroendocrine markers and explore its clinicopathologic features,thus improving the understanding of its clinical diagnosis and management.CASE SUMMARY We report the case of a 48-year-old patient with SCCP negative for common sensitive neuroendocrine-staining indicators.Dysuria was the first symptom,and rectal examination revealed a hard prostate,palpable nodules,diffuse prostate enlargement,no pressure pain,no blood staining in the finger sleeve,1.33 ng/mL total prostate-specific antigen level,and a free-to-total prostate-specific antigen ratio of 0.21 ng/mL.Ultrasound suggested a prostate size of 5.3 cm×5.8 cm×5.6 cm,and magnetic resonance imaging suggested prostate cancer.The lower posterior bladder wall,rectal mesentery,and bilateral seminal vesicles were invaded,with multiple lymph node metastases in the pelvis.A whole-body bone scan suggested an abnormally active multiple bone metabolism and possible bone metastases.Head and lungs computed tomography revealed no significant nodal shadow.Following a pathological diagnosis of SCCP after a prostate puncture,with negative indicators of common sensitive neuroendocrine staining,chemotherapy was administered;the patient died 4-5 mo after SCCP diagnosis.CONCLUSION SCCP is a rare disease characterized by atypical clinical symptoms,limited treatment options,a short survival period,and a poor prognosis.
机构地区 Department of Urology
出处 《World Journal of Clinical Cases》 SCIE 2022年第5期1630-1638,共9页 世界临床病例杂志
基金 Supported by the National Natural Science Foundation of China,No.81972395,and No.82060464.
  • 相关文献

参考文献1

二级参考文献26

  • 1American Cancer Society (ACS). Cancer Facts and Figures 2008.
  • 2Helpap B, Kollermann J, Oehler U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol Int 1999; 62: 133-8.
  • 3Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-18.
  • 4Okada H, Shirakawa T, Miyake H, Gotoh A, Fujisawa M, et al. Establishment of a prostatic small-cell carcinoma cell line (SO-MI). Prostate 2003; 56: 231-8.
  • 5Morton CL, Houghton PJ. Establishment of human tumor xenograts in immunodeficient mice. Nat Protoc 2007; 2: 247-50.
  • 6Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009; 69: 3364-73.
  • 7Aubert C, Rouge F, Galindo JR. Tumorigenicity of human malignant melanocytes in nude mice in relation to their differentiation in vitro. J Natl Cancer Inst 1980; 64: 1029-40.
  • 8Li H, Fu X, Zhang L, Sun T, Wang J. In vivo dedifferentiation of human epidermal cells. Cell Biol Int 2007; 31: 1436-41.
  • 9Steiner MS)Molecular Biology of Prostate Growth Regulation. In: Lepor H, editor. Prostatic Diseases. Philadelphia, W.B. Saunders Co.; 2002. p41-57.
  • 10Taylor RA, Risbridger GE Prostatic tumor stroma: a key player in cancer progression. Curr Cancer Drug Targets 2008; 8: 490-7.

共引文献1

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部